Despite a challenging venture capital environment, Hatteras Venture Partners closed two new investment funds totaling $200 million, focused on seed- and early-stage biotech companies. The firm's success in fundraising highlights persistent investor interest in innovative life sciences startups amid broader market caution. The capital injection is set to accelerate development pipelines for emergent biotech firms navigating clinical and commercial milestones in an increasingly competitive landscape.